BRAF inhibition has been an instant, although short-lasting, success in BRAF-mutated melanoma treatment. Novel data by Berger et al. now suggest that BRAF-inhibitor-mediated “priming to death” facilitates tumor necrosis factor–related apoptosis-inducing ligand–mediated apoptosis. We give an overview about the importance of the crosstalk of extrinsic and mitochondrial apoptotic signaling and propose other combination therapies that may prevent or overcome secondary resistance in melanoma
Since the discovery of BRAF mutations in over 50% of melanomas, various small molecule inhibitors ag...
SummaryDespite success with BRAFV600E inhibitors, therapeutic responses in patients with metastatic ...
The discovery of the BRAFV600E mutation led to the development of vemurafenib (PLX4032), a selective...
BRAF inhibition has been an instant, although short-lasting, success in BRAF-mutated melanoma treatm...
Mutated BRAF represents a critical oncogene in melanoma, and selective inhibitors have been approved...
About 50% of metastatic melanomas harbor BRAF V600 mutations, most commonly a V600E substitution, wh...
The melanoma treatment landscape has been revolutionized by the rational design of small molecules t...
Melanoma of the skin has become a prime example for demonstrating the success of targeted cancer the...
Understanding the role of mitogen-activated protein kinase (MAPK) pathway-activating mutations in th...
SummaryUnresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, t...
Patients with metastatic melanoma bearing V600 mutations in BRAF oncogene clinically benefit from th...
Treatment of BRAF-mutant metastatic melanoma with mitogen-activated protein kinase (MAPK) pathway ta...
BRAF inhibitor therapy may provide profound initial tumor regression in metastatic melanoma with BRA...
Background: Melanoma is the most aggressive and deadly form of skin cancer with increasing case numb...
Background The introduction of targeted therapies for the treatment of BRAF-mutant melanomas have im...
Since the discovery of BRAF mutations in over 50% of melanomas, various small molecule inhibitors ag...
SummaryDespite success with BRAFV600E inhibitors, therapeutic responses in patients with metastatic ...
The discovery of the BRAFV600E mutation led to the development of vemurafenib (PLX4032), a selective...
BRAF inhibition has been an instant, although short-lasting, success in BRAF-mutated melanoma treatm...
Mutated BRAF represents a critical oncogene in melanoma, and selective inhibitors have been approved...
About 50% of metastatic melanomas harbor BRAF V600 mutations, most commonly a V600E substitution, wh...
The melanoma treatment landscape has been revolutionized by the rational design of small molecules t...
Melanoma of the skin has become a prime example for demonstrating the success of targeted cancer the...
Understanding the role of mitogen-activated protein kinase (MAPK) pathway-activating mutations in th...
SummaryUnresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, t...
Patients with metastatic melanoma bearing V600 mutations in BRAF oncogene clinically benefit from th...
Treatment of BRAF-mutant metastatic melanoma with mitogen-activated protein kinase (MAPK) pathway ta...
BRAF inhibitor therapy may provide profound initial tumor regression in metastatic melanoma with BRA...
Background: Melanoma is the most aggressive and deadly form of skin cancer with increasing case numb...
Background The introduction of targeted therapies for the treatment of BRAF-mutant melanomas have im...
Since the discovery of BRAF mutations in over 50% of melanomas, various small molecule inhibitors ag...
SummaryDespite success with BRAFV600E inhibitors, therapeutic responses in patients with metastatic ...
The discovery of the BRAFV600E mutation led to the development of vemurafenib (PLX4032), a selective...